At close: 4:00:01 PM EST
After hours: 4:39:13 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 1 | 4 | 4 |
| Avg. Estimate | -0.19 | -0.13 | -0.85 | -0.81 |
| Low Estimate | -0.34 | -0.13 | -1.1 | -1.71 |
| High Estimate | -0.07 | -0.13 | -0.62 | -0.31 |
| Year Ago EPS | -0.27 | -0.27 | -0.86 | -0.85 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 2 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.32 | -0.25 | -0.23 | -0.21 |
| EPS Actual | -0.27 | -0.27 | -0.18 | -0.25 |
| Difference | 0.05 | -0.03 | 0.05 | -0.04 |
| Surprise % | 16.92% | -10.20% | 23.08% | -17.19% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.19 | -0.13 | -0.85 | -0.81 |
| 7 Days Ago | -0.21 | -0.11 | -0.96 | -0.8 |
| 30 Days Ago | -0.21 | -0.11 | -0.88 | -0.81 |
| 60 Days Ago | -0.21 | -0.11 | -0.88 | -0.81 |
| 90 Days Ago | -0.21 | -0.16 | -0.89 | -0.85 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | 1 | -- | 1 | 2 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 2 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CGTX | 31.48% | 51.85% | 0.87% | 5.57% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/27/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/4/2024 |
| Maintains | Chardan Capital: Buy to Buy | 10/31/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/12/2024 |
| Downgrade | B. Riley Securities: Buy to Neutral | 8/6/2024 |
Related Tickers
INAB IN8bio, Inc.
0.2816
-1.12%
TFFP TFF Pharmaceuticals, Inc.
0.0650
-60.05%
CRVO CervoMed Inc.
1.9500
+2.63%
APTO Aptose Biosciences Inc.
0.1892
-1.97%
ELEV Elevation Oncology, Inc.
0.6400
+0.61%
UNCY Unicycive Therapeutics, Inc.
0.7000
-2.03%
EYEN Eyenovia, Inc.
0.0816
-2.28%
VRPX Virpax Pharmaceuticals, Inc.
0.3530
-11.75%
SPRC SciSparc Ltd.
0.2290
-16.67%
AVXL Anavex Life Sciences Corp.
9.18
+8.51%